Management of fertility in women with familial hypercholesterolaemia: Summary of NICE guidance

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 116, Issue 4, 2009, Pages 478-479

  Thorogood, M ^a   Seed, M ^b   De Mott, K ^c  

^a UNIVERSITY OF WARWICK   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c ROYAL COLLEGE OF GENERAL PRACTITIONERS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ORAL CONTRACEPTIVE AGENT; RESIN;

AORTA STENOSIS; BREAST FEEDING EDUCATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTRACEPTION; DRUG EFFICACY; FAMILIAL HYPERCHOLESTEROLEMIA; FERTILITY; FETUS DISEASE; HUMAN; ISCHEMIC HEART DISEASE; LACTATION; NOTE; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; RISK ASSESSMENT;

ADULT; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIA TYPE II; HYPOLIPIDEMIC AGENTS; INFERTILITY, FEMALE; PRACTICE GUIDELINES AS TOPIC; PRECONCEPTION CARE; PREGNANCY; PREGNANCY COMPLICATIONS; PRENATAL CARE;

EID: 60449092087     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/j.1471-0528.2008.02084.x     Document Type: Note

References (12)

1. Austin MA, Hutter CM, Zimmern RL, Humphries SE. Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review. Am J Epidemiol 2004 160 : 407 20.
2. Humphries SE, Whittall RA, Hubbart CS, Maplebeck S, Cooper JA, Soutar AK, et al. Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk. J Med Genet 2006 43 : 943 9.
3. Marks D, Thorogood M, Neil SM, Humphries SE, Neil HAW. Cascade screening for familial hypercholesterolaemia: implications of a pilot study for national screening programmes. J Med Screen 2006 13 : 156 9.
4. Scientific Steering Committee on behalf of the Simon Broome Register Group. Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Atherosclerosis 1999 142 : 105 12.
5. Neil A, Cooper J, Betteridge J, Capps N, McDowell I, Durrington P, Seed M, Humphries S on behalf of the Simon Broome Familial Hyperlipidaemia Register Group. Reductions in all-cause, cancer and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. Eur Heart J 2008 29 : 2625 33.
6. DeMott K, Nherera L, Shaw EJ, Minhas R, Humphries SE, Kathoria M, et al. Clinical Guidelines and Evidence Review for Familial Hypercholesterolaemia: The Identification and Management of Adults and Children with Familial Hypercholesterolaemia. London : National Collaborating Centre for Primary Care and Royal College of General Practitioners, 2008.
7. Amundsen AL, Khoury J, Iversen PO, Bergei C, Ose L, Tonstad S, et al. Marked changes in plasma lipids and lipoproteins during pregnancy in women with familial hypercholesterolemia. Atherosclerosis 2006 189 : 451 7.
8. Manson JM, Freyssinges C, Ducrocq MB, Stephenson WP. Postmarketing surveillance of lovastatin and simvastatin exposure during pregnancy. Reprod Toxicol 1996 10 : 439 46.
9. Edison RJ, Muenke M. Mechanistic and epidemiologic considerations in the evaluation of adverse birth outcomes following gestational exposure to statins. Am J Med Genet 2004 131A : 287 98.
10. Ofori B, Evelyne R, Bérard A. Risk of congenital anomalies in pregnant users of statin drugs. Br J Clin Pharmacol 2007 64 : 496 509.
11. Spitzer WO, Faith JM, MacRae KD. Myocardial infarction and third generation oral contraceptives: aggregation of recent studies. Hum Reprod 2002 17 : 2307 14.
12. Simonson SG, Martin PD, Warwick MJ, Mitchell PD, Schneck DW. The effect of rosuvastatin on oestrogen and progestin pharmacokinetics in healthy women taking an oral contraceptive. Br J Clinical Pharmacol 2004 57 : 279 86.